German court orders BioNTech to provide data on COVID vaccine harms

On Tuesday, the lead attorney in a lawsuit brought by COVID vaccine victims against BioNTech released a ruling from a German court confirming that the pharmaceutical company must disclose data on vaccine injuries.

BioNTech appealed an earlier court ruling that ordered the company to disclose the injury data. The company lost its appeal.

Let’s not lose touch… Your government and Big Tech are actively trying to censor the information reported by TheExpose to serve their own needs. Sign up for our emails now to make sure you get the latest uncensored news in your inbox…

Stay tuned!

Stay up to date with news updates via email

Enter your name
Enter your email
Are you human? 3 + 6 =
Tobias Ulbrich , a partner at the Hamburg-based law firm Rogert & Ulbrich, is the lead attorney for several plaintiffs suing BioNTech and Pfizer for alleged side effects from the Comirnaty COVID vaccine.

Ulbrich’s legal strategy focuses on challenging the regulatory assessment that the vaccine has a positive risk-benefit profile and securing internal manufacturer data to prove disproportionate harm.

In a significant procedural development in March 2026, the Aurich Regional Court ordered BioNTech to hand over 32 categories of internal safety, toxicity, and production records, confirming that injured plaintiffs have a right to access the manufacturer’s own data under German pharmaceutical law.

This ruling was upheld earlier this week when the Oberlandesgericht Oldenburg dismissed BioNTech’s appeal. On Tuesday, Ulbrich tweeted: "The Oldenburg Higher Regional Court dismisses the appeal of BioNTech Manufacturing GmbH. This makes the partial judgment of the Aurich Regional Court final and binding. BioNTech Manufacturing GmbH must comply with the final partial judgment of the Aurich Regional Court and provide the plaintiff with the information required therein.

The Aurich Regional Court has ordered BioNTech to provide the plaintiff with information on the effects and side effects of batches FE6975 and 1D020A, of which the defendant was aware from December 21, 2020, until the last oral hearing, as well as further conclusions regarding the assessment of the tolerability of the harmful effects of Comirnaty, insofar as they relate to the complaints raised by the plaintiff (including autoimmune diseases, circulatory disorders, vascular occlusions, cardiac arrhythmias, hyperinflammation syndrome, menstrual disorders, nervous system dysfunctions, tinnitus, POTS, PEM, ME/CFS).

Specifically, the information required includes on:

• The toxicity and immunological effects of the lipid nanoparticles ALC-0159 and ALC-0315, as well as their purity levels.

• Suppliers and manufacturing technology of the disputed batch.

• Properties of the spike protein (Furin cleavage site, P2-Lock, possible HIV sequence clusters, neuropilin cleavage site, membrane anchor).

• Pharmacovigilance data on matching lesions.

• Genotoxicity, possible plasmid DNA/SV40 promoter aspects.

• Effects on fertility, preliminary reports of abortions/stillbirths.

• OncomiRs, gender-specific risks.

• Employee or special batches and additional technical/pharmacological points.